Ascletis® Pharmaceuticals Commences Phase IIa Study of Oral GLP-1R Agonist ASC30 in U.S. for Obesity and Overweight Patients
[City, State] – July 2, 2025 – Ascletis Pharmaceuticals (HKEX: 1672), a leading biopharmaceutical company, today announced a significant milestone in its ongoing commitment to addressing metabolic diseases. The company has successfully dosed the first participants in its U.S.-based, 13-week Phase IIa clinical study evaluating ASC30, a novel, small molecule oral glucagon-like peptide-1 receptor (GLP-1R) agonist. This study aims to assess the safety, tolerability, and preliminary efficacy of ASC30 in individuals diagnosed with obesity or overweight.
GLP-1R agonists have emerged as a promising therapeutic class for managing weight and improving metabolic health. ASC30 represents Ascletis’ dedication to developing innovative oral formulations that offer greater convenience and accessibility for patients compared to traditional injectable therapies. This Phase IIa study is designed to provide critical data on how ASC30 performs in a targeted patient population, paving the way for further clinical development.
The study’s commencement marks a pivotal moment for Ascletis and for patients seeking new treatment options for weight management. By investigating an oral small molecule, Ascletis is striving to overcome existing barriers to GLP-1R agonist therapy, potentially enhancing patient adherence and overall treatment outcomes. The research team will carefully monitor the safety profile of ASC30 throughout the 13-week treatment period, alongside evaluating its impact on key metabolic markers and body weight.
“We are delighted to announce the initiation of our Phase IIa study for ASC30 in the United States,” said [Name and Title of Ascletis Spokesperson – if available in the source, otherwise omit or use a placeholder like ‘a spokesperson for Ascletis’]. “This study represents a crucial step forward in our mission to develop effective and patient-friendly treatments for obesity and overweight. We are encouraged by the potential of ASC30 to offer a convenient oral alternative and are eager to gather the data that will inform our future development plans.”
The trial is being conducted at multiple sites across the U.S., adhering to the highest standards of clinical research ethics and patient safety. Ascletis remains committed to advancing the science of metabolic disease treatment and is optimistic about the potential of ASC30 to make a meaningful difference in the lives of individuals struggling with weight-related health challenges.
Further updates on the study’s progress and findings will be shared as they become available.
About Ascletis Pharmaceuticals Ascletis Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of viral diseases and metabolic diseases. The company’s robust pipeline includes a range of novel drug candidates, with a particular emphasis on oral formulations for increased patient convenience. Ascletis is dedicated to improving patient lives through scientific excellence and a patient-centric approach.
Forward-Looking Statements This announcement contains forward-looking statements regarding the development of ASC30. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Ascletis Pharmaceuticals undertakes no obligation to update any forward-looking statements.
Contact: [Insert PR Newswire Contact Information Here if available or relevant]
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30’ at 2025-07-02 23:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.